Lenalidomide Patent Expiration
Lenalidomide is used for treating mantle cell lymphoma, multiple myeloma, and myelodysplastic syndromes. It was first introduced by Bristol Myers Squibb
Lenalidomide Patents
Given below is the list of patents protecting Lenalidomide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Revlimid | US8741929 | Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas | Mar 08, 2028 | Bristol Myers Squibb |
| Revlimid | US7465800 | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione | Apr 27, 2027 | Bristol Myers Squibb |
| Revlimid | US7855217 | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Nov 24, 2024
(Expired) | Bristol Myers Squibb |
| Revlimid | US7468363 | Methods for treatment of cancers using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Oct 07, 2023
(Expired) | Bristol Myers Squibb |
| Revlimid | US7968569 | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Oct 07, 2023
(Expired) | Bristol Myers Squibb |
| Revlimid | US8492406 | Methods for treatment of follicular lymphoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione |
Oct 07, 2023
(Expired) | Bristol Myers Squibb |
| Revlimid | US8530498 | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione |
May 15, 2023
(Expired) | Bristol Myers Squibb |
| Revlimid | US8648095 | Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor |
May 15, 2023
(Expired) | Bristol Myers Squibb |
| Revlimid | US9101621 | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
May 15, 2023
(Expired) | Bristol Myers Squibb |
| Revlimid | US9101622 | Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone |
May 15, 2023
(Expired) | Bristol Myers Squibb |
| Revlimid | US9155730 | Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent |
May 15, 2023
(Expired) | Bristol Myers Squibb |
| Revlimid | US9393238 | Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent |
May 15, 2023
(Expired) | Bristol Myers Squibb |
| Revlimid | US7189740 | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
Apr 11, 2023
(Expired) | Bristol Myers Squibb |
| Revlimid | US8404717 | Methods of treating myelodysplastic syndromes using lenalidomide |
Apr 11, 2023
(Expired) | Bristol Myers Squibb |
| Revlimid | US9056120 | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
Apr 11, 2023
(Expired) | Bristol Myers Squibb |
| Revlimid | US6315720 | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
Oct 23, 2020
(Expired) | Bristol Myers Squibb |
| Revlimid | US6561977 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol Myers Squibb |
| Revlimid | US6755784 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol Myers Squibb |
| Revlimid | US8315886 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol Myers Squibb |
| Revlimid | US8626531 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol Myers Squibb |
| Revlimid | US5635517 | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines |
Oct 04, 2019
(Expired) | Bristol Myers Squibb |
| Revlimid | US5635517 | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines |
Oct 04, 2019
(Expired) | Bristol Myers Squibb |
| Revlimid | US6045501 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol Myers Squibb |
| Revlimid | US6561976 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol Myers Squibb |
| Revlimid | US6908432 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol Myers Squibb |
| Revlimid | US8204763 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol Myers Squibb |
| Revlimid | US8589188 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol Myers Squibb |
| Revlimid | US6281230 | Isoindolines, method of use, and pharmaceutical compositions |
Jul 24, 2016
(Expired) | Bristol Myers Squibb |
| Revlimid | US6555554 | Isoindolines, method of use, and pharmaceutical compositions |
Jul 24, 2016
(Expired) | Bristol Myers Squibb |
| Revlimid | US7119106 | Pharmaceutical compositions of 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline |
Jul 24, 2016
(Expired) | Bristol Myers Squibb |
| Revlimid | US8288415 | Pharmaceutical compositions of 3-(4-amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione |
Jul 24, 2016
(Expired) | Bristol Myers Squibb |
| Revlimid | US8288415 | Pharmaceutical compositions of 3-(4-amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione |
Jul 24, 2016
(Expired) | Bristol Myers Squibb |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Lenalidomide's patents.
Latest Legal Activities on Lenalidomide's Patents
Given below is the list recent legal activities going on the following patents of Lenalidomide.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 19 Nov, 2025 | US8741929 |
| Expire Patent | 13 Oct, 2025 | US8530498(Litigated) |
| Maintenance Fee Reminder Mailed | 29 Sep, 2025 | US8648095(Litigated) |
| Expire Patent | 25 Aug, 2025 | US8492406 |
| Expire Patent | 28 Apr, 2025 | US8404717 |
| Maintenance Fee Reminder Mailed | 28 Apr, 2025 | US8530498(Litigated) |
| Maintenance Fee Reminder Mailed | 10 Mar, 2025 | US8492406 |
| Maintenance Fee Reminder Mailed | 11 Nov, 2024 | US8404717 |
| Expire Patent | 26 Aug, 2024 | US9393238 |
| Maintenance Fee Reminder Mailed Critical
| 11 Mar, 2024 | US9393238 |
Lenalidomide's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Lenalidomide:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
